

Contact: Mari Anne Snow  
Email: [info@eascrabiotech.com](mailto:info@eascrabiotech.com)  
Phone: (401) 286-9828

### **Eascra Biotech Selected for 2024 Flagship U.S. MassChallenge Accelerator**

*Nanomedicine leader invited to participate in prestigious program for high-impact, high-potential startups*

Boston, July 30, 2024 – MassChallenge has selected [Eascra Biotech](#) to participate in the 2024 MassChallenge program. Eascra was one of more than 1,300 startups to apply this year. Only 128 high-potential startups were selected for the program’s flagship program in the U.S.

“Earning a position in this prestigious MassChallenge cohort is an important opportunity for us,” said Mari Anne Snow, CEO and co-founder of Eascra. “The program will help accelerate our mission to advance therapeutic delivery solutions and precise patient care. As we continue to innovate and bring our cutting-edge nanotechnologies to market, the support from MassChallenge and its network will be invaluable.”

Eascra will gain access to MassChallenge’s global network of partners, experts, and mentors, benefit from introductions to investors, and gain access to equity-free grants and awards. MassChallenge companies combined have raised almost \$10 billion in funding over the years. Eascra will be eligible for special programs like the Technology in Space Prize, which awards up to \$500,000 in nondilutive funding and would allow Eascra Biotech’s product to return to the International Space Station for advanced testing and development.

“Eascra would relish the opportunity to return to the International Space Station for more research and development,” said Snow. Eascra has already participated in three different missions to the International Space Station for research and to test different manufacturing methodologies, advancing Eascra’s Janus base nanoparticle’s (JBNps) use for arthritis and cancer treatments.

The MassChallenge program will provide crucial mentorship and opportunities for Eascra Biotech to achieve its mission to bring its JBNp technology to market to help patients and support the future of medicine.

### **About Eascra Biotech**

Eascra Biotech ([eascrabiotech.com](http://eascrabiotech.com)) is an early-stage nanomedicine startup providing an advanced therapeutic delivery platform capable of delivering RNA, gene editing, and other therapeutics to hard-to-reach treatment sites, such as cartilage, solid tumors, and other cells. Our mission is to advance science for the benefit of humankind. Eascra’s proprietary delivery mechanism, a Janus Base Nanoparticle (JBNp) invented by Eascra co-founder, Dr. Yupeng Chen, mimics DNA and is customizable for different treatment indications. Eascra is working with NASA, the ISS National Lab, and private space company Axiom Space to accelerate our go-to-market strategy. We are actively seeking commercial partnerships with companies in

need of innovative delivery mechanisms to expedite the development of cutting-edge treatments that enhance patient outcomes.

### **About MassChallenge**

MassChallenge is the global network for innovators. Headquartered in the United States with eight locations worldwide, it is the non-profit's mission to help bold entrepreneurs disrupt the status quo and create sustainable change. Since launching in 2009, MassChallenge has run programs in 24 countries, supported more than 4,000 startups from around the world, and awarded over \$18M in equity-free cash and prizes. Learn more about MassChallenge at [masschallenge.org](http://masschallenge.org).

###